Navigation Links
Nile Therapeutics Reports 2008 First Quarter Financial Results
Date:5/15/2008

SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced financial results for the first quarter ended March 31, 2008.

Net operating loss for the first quarter of 2008 was $3.1 million, or $0.13 per share, compared to $0.8 million, or $0.05 per share, for the first quarter of 2007. Weighted average shares outstanding for the first quarter for 2008 and 2007 were 24.1 million and 13.8 million, respectively.

Nile reported no revenue during the first quarter of 2008 and 2007. Research and development expenses were $2.0 million for the first quarter of 2008 compared to $0.6 million for the first quarter of 2007. General and administrative expenses were $1.2 million for the first quarter of 2008 compared to $0.2 million for the first quarter of 2007.

At March 31, 2008, Nile had cash and cash equivalents of $13.66 million compared to $16.23 million on December 31, 2007. This $2.57 million decrease occurred as cash was used for operations.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in clinical studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This pr
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... involve a range of resource and environmental problems. ... resin and a clever recycling strategy, Uppsala researchers ... alternative. Their study will be presented soon in ... think our discovery can open several doors to ... the future, says Daniel Brandell, Associate Professor at ...
(Date:9/29/2014)... , September 29, 2014 ... research report "Epigenetics Market by Product (Modifying Enzymes, ... Kit, Bisulphite Conversion Kit, Reagents), by Research ... - Global Forecast to 2019", published by ... major drivers, restraints, opportunities, current market trends, ...
(Date:9/29/2014)... 29, 2014 ACEA Biosciences, Inc. ... the 2014 iCELLigence Research Grant for his proposal ... instrument is an impedance based real-time label-free cellular ... Department of Biomedical Engineering at Yale University currently ... projects in Professor Rong Fan's laboratory ...
(Date:9/29/2014)... YORK , Sept. 29, 2014 ... and The Channel Group ("TCG"), a leader in ... advisors, have formed an alliance to expand the ... prospective clients. With the alliance, Burnham Securities will ... the scientific, clinical medicine and management in healthcare ...
Breaking Biology Technology:Smart, eco-friendly new battery to solve problems 2Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3
... Companies will Present at the Largest Marketplace for Emerging ... and CTSI today announced that more than 100 leading ... partners will be showcased in the 4th Annual TechConnect ... R. Brown Convention Center in Houston, Texas. Held ...
... Development and InnovationMOUNTAIN VIEW, Calif., April 22 ... Pharmaceuticals & Biotechnology group assesses a variety of ... in cancer treatment. Physicians, nurses and patients ... reconstitution, home vs. office administration parameters, and barriers ...
... 22 GeneGo, Inc., a leading provider of software ... , today announced that the University of Cardiff has ... researchers will have access to GeneGo,s MetaCore, training and ... their partner relationship with GeneGo to provide a pathway ...
Cached Biology Technology:TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 2Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 3Cardiff University Becomes a GeneGo Center of Excellence 2
(Date:9/29/2014)... In order to support the world,s needs to ... and more, new and more efficient catalytic materials ... researchers, including several from Wayne State University, is ... new grant from the National Science Foundation. , ... of Multicomponent Materials for Electrocatalytic Cascade Reactions," was ...
(Date:9/29/2014)... five-year, $6 million grant for clinical research and ... of safe and effective treatments for cocaine addiction. ... Institutes of Health, National Institute on Drug Abuse, ... for Cocaine Use Disorder to oversee preclinical and ... moving forward with more expensive large-scale clinical trials. ...
(Date:9/29/2014)... A review article published online in Behavioral ... happen in the brain as a result of chronic ... sleep cycle. , Clinical assessments and research indicate ... severely disrupted sleep. This can occur when people are ... when they are abstaining. , "Sleep-wake disturbances can ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2New VCU center to target cocaine addiction 2
... EMBO announced today the selection of 23 young ... network of 315 current and past Young Investigators. ... years of age who have established their first laboratories ... in ten European countries, Israel and Singapore. The success ...
... the University of Sheffield,s Faculty of Engineering, have shown ... turning it into glass reduces its volume by 85-95 ... plutonium, creating a stable end product. The approach ... wastes generated during the eventual clean-up of the damaged ...
... to find the necessities of life. It,s a complex task, ... environment to navigate the safest and fastest routes to food ... certain important events, such as finding a meal, will occur. ... fundamental behaviors, navigation and the anticipation of a reward, had ...
Cached Biology News:Volume of nuclear waste could be reduced by 90 percent, says new research 2Anticipation and navigation: Do your legs know what your tongue is doing? 2Anticipation and navigation: Do your legs know what your tongue is doing? 3Anticipation and navigation: Do your legs know what your tongue is doing? 4
...
... Orange G Dye runs faster than ... standard agarose gels.,Orange G dye migrates ... long. The migration at this size,prevents ... and,conveniently indicates the front of DNA ...
... loading solution, Type I ... polyacrylamide and agarose gel ... and offers the advantage ... (bromphenol blue and xylene ...
... SilverSNAP Stain for Mass Spectrometry Applications ... spectrometry (MS) has emerged as a powerful ... of 2-D gels is now an important ... that leads ultimately to identification of specific ...
Biology Products: